IDEXX Laboratories, Inc. (IDXX) Given Consensus Recommendation of “Hold” by Analysts
IDEXX Laboratories, Inc. (NASDAQ:IDXX) has received an average recommendation of “Hold” from the nine research firms that are presently covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and six have given a buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $187.33.
Several equities research analysts have issued reports on IDXX shares. Canaccord Genuity reaffirmed a “buy” rating and set a $180.00 price target on shares of IDEXX Laboratories in a research note on Friday, October 6th. BidaskClub lowered IDEXX Laboratories from a “hold” rating to a “sell” rating in a research note on Saturday, December 16th. Aegis reaffirmed a “sell” rating on shares of IDEXX Laboratories in a research note on Friday, December 8th. Zacks Investment Research raised IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $184.00 price target for the company in a research note on Tuesday, October 24th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $185.00 price target on shares of IDEXX Laboratories in a research note on Tuesday, October 24th.
In other news, Chairman Jonathan W. Ayers sold 54,000 shares of the business’s stock in a transaction dated Tuesday, November 7th. The stock was sold at an average price of $151.32, for a total value of $8,171,280.00. Following the completion of the sale, the chairman now owns 1,064,573 shares of the company’s stock, valued at approximately $161,091,186.36. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Jonathan W. Ayers sold 18,000 shares of the business’s stock in a transaction dated Tuesday, January 9th. The shares were sold at an average price of $165.15, for a total value of $2,972,700.00. Following the completion of the sale, the chief executive officer now directly owns 1,077,112 shares of the company’s stock, valued at approximately $177,885,046.80. The disclosure for this sale can be found here. In the last three months, insiders sold 130,160 shares of company stock valued at $20,019,685. 2.77% of the stock is currently owned by corporate insiders.
IDEXX Laboratories (IDXX) traded up $3.57 during trading on Tuesday, reaching $176.81. The company had a trading volume of 242,755 shares, compared to its average volume of 482,989. IDEXX Laboratories has a twelve month low of $116.54 and a twelve month high of $173.82. The company has a debt-to-equity ratio of -12.48, a quick ratio of 0.77 and a current ratio of 0.95. The stock has a market capitalization of $15,370.00, a PE ratio of 57.41, a price-to-earnings-growth ratio of 2.34 and a beta of 0.42.
IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Tuesday, October 31st. The company reported $0.79 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.74 by $0.05. IDEXX Laboratories had a negative return on equity of 336.64% and a net margin of 14.55%. The firm had revenue of $492.00 million during the quarter, compared to analyst estimates of $492.94 million. During the same quarter in the previous year, the company posted $0.62 earnings per share. The company’s revenue was up 9.7% compared to the same quarter last year. equities research analysts predict that IDEXX Laboratories will post 3.24 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “IDEXX Laboratories, Inc. (IDXX) Given Consensus Recommendation of “Hold” by Analysts” was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another publication, it was stolen and reposted in violation of international trademark and copyright legislation. The correct version of this news story can be read at https://www.watchlistnews.com/idexx-laboratories-inc-idxx-given-consensus-recommendation-of-hold-by-analysts/1809361.html.
IDEXX Laboratories Company Profile
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.